Skip to content
verana-health-logo-inverted
  • Clinicians
    • MIPS Advisory Offerings
    • Practice Insights
    • Verana Trial Connect
    • Verana Quality Measures
  • Life Sciences
    • Clinical Development
    • HEOR & Medical Affairs
    • Commercialization
  • Research
  • Therapeutic Area
    • Oncology
      • Acute Myeloid Leukemia
      • Breast Cancer
      • Chronic Lymphocytic Leukemia
      • Colorectal Cancer
      • Follicular Lymphoma
      • Large B-Cell Lymphoma
      • Lung Cancer
      • Marginal Zone Lymphoma
      • Melanoma
      • Multiple Myeloma
      • Myelodysplastic Syndrome
      • Ovarian Cancer
    • Ophthalmology
      • Anti-VEGF
      • Diabetic Retinopathy
      • Dry Eye Disease
      • Cataracts
      • Geographic Atrophy
      • Glaucoma
      • Neovascular AMD
      • Retinitis Pigmentosa
      • Thyroid Eye Disease
      • Uveitic Macular Edema
      • Qdata Explorer
    • Urology
      • Benign Prostatic Hyperplasia
      • Bladder Cancer
      • Prostate Cancer
    • Neurology
      • Multiple Sclerosis
      • Parkinson’s Disease
      • Spinal Muscular Atrophy
  • Solutions
    • Clinical Research Solutions
      • Trial Design
      • Protocol Optimization & Site Selection
      • Patient Recruitment
      • Prospective Evidence Generation (PEG)
    • Clinical Trials
      • Site Explorer
    • Market Insights
      • Market Tracking
      • Brand Switching
      • Prescriber Mapping
    • RWE Studies
      • Patient Segmentation
      • Safety Studies
      • Natural History of Disease / Disease Progression
      • Comparative Effectiveness
      • Treatment Patterns & Outcomes
      • Healthcare Resource Utilization (HCRU) Cost
    • Phase IV Studies / Surveillance
  • About Us
    • About
      • Evolve Registry
    • Team
    • Press
    • Blog
    • Careers
    • Partners
      • Societies
      • CROs
      • Technology and Data
    • Privacy
      • Privacy Policy
      • Patient Privacy
Contact Us

Prognostic value of the absolute lymphocyte to monocyte (ALC/AMC) ratio on overall survival among patients with mantle cell lymphoma

← Predictive value of the patient reported outcome “living with cancer” instrument on overall survival in advanced cancer patients: A tool for guiding timing of palliative care consultationsTreatment of Peripheral T-Cell Lymphoma in Community Settings →
verana-health-logo-inverted

© 2026 Verana Health. All Rights Reserved.

San Francisco
New York
Knoxville
  • Privacy Policy
  • Cookie Policy
Back to Top